Literature DB >> 2142011

Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome.

S Flament1, A Delacourte, D M Mann.   

Abstract

Six different brain areas from 6 patients with Down's syndrome (DS) of different ages were studied in respect of their Tau protein content using the western-blot technique. They were also studied histologically using a Palmgren (silver staining) method in order to reveal the presence of NFT and SP. The results of these studies show that Tau 64 and 69, two pathological Tau variants recently described in the brains of patients with Alzheimer's disease (AD), are also present in the brains of patients with DS. Alkaline phosphatase treatment demonstrates that their heavy molecular weight is due, as in AD, to an abnormal phosphorylation of Tau proteins. The results of this study show that the detection of Tau 64 and 69 in the brain of these patients is correlated with the presence of neurofibrillary tangles (NFT) and senile plaques (SP). These findings confirm that DS can act as a model for the study of the pathological events that occur in AD. Moreover, they suggest that the abnormal phosphorylation of Tau proteins, enhancing a shift of their electrophoretic mobility, might be an important step among the sequence of events that characterize neurofibrillary degeneration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142011     DOI: 10.1016/0006-8993(90)90891-e

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

Review 1.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

2.  Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments.

Authors:  M G Spillantini; M Goedert; R A Crowther; J R Murrell; M R Farlow; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Pathological proteins Tau 64 and 69 are specifically expressed in the somatodendritic domain of the degenerating cortical neurons during Alzheimer's disease. Demonstration with a panel of antibodies against Tau proteins.

Authors:  A Delacourte; S Flament; E M Dibe; P Hublau; B Sablonnière; B Hémon; V Shérrer; A Défossez
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 4.  Probing modifications of the neuronal cytoskeleton.

Authors:  L C Doering
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

5.  Functional domains on chemically modified tau protein.

Authors:  G A Farías; C Vial; R B Maccioni
Journal:  Cell Mol Neurobiol       Date:  1993-04       Impact factor: 5.046

6.  Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau.

Authors:  G Farías; C González-Billault; R B Maccioni
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

Review 7.  Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.

Authors:  Isidro Salcedo; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

8.  Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures.

Authors:  Pasquale Picone; Rita Carrotta; Giovanna Montana; Maria Rita Nobile; Pier Luigi San Biagio; Marta Di Carlo
Journal:  Biophys J       Date:  2009-05-20       Impact factor: 4.033

9.  Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome.

Authors:  Zhihou Liang; Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Jerzy Wegiel; Cheng-Xin Gong
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

10.  Tau in Alzheimer's disease and Down's syndrome is insoluble and abnormally phosphorylated.

Authors:  D P Hanger; J P Brion; J M Gallo; N J Cairns; P J Luthert; B H Anderton
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.